Ex 7 28 Cash To Monthly Cash Expenses Ratio Allos Therapeutics Inc Is A Biopharmaceu 1418737
EX 7-28 Cash to monthly cash expenses ratio
Allos Therapeutics, Inc., is a biopharmaceutical company that develops drugs for the treatment of cancer. Allos Therapeutics reported the following financial data (in thousands) for three recent years:
For Years Ended December 31
Year 3
Year 2
Year 1
Cash and cash equivalents
$ 48,402
$141,423
$ 30,696
Net cash flows from operations
(63,656)
(62,199)
(42,850)
a. Determine the monthly cash expenses for Year 3, Year 2, and Year 1. Round to one decimal place.
b. Determine the ratio of cash to monthly cash expenses for Year 3, Year 2, and Year 1 as of December 31. Round to one decimal place.
c. Based on (a) and (b), comment on Allos Therapeutics’ ratio of cash to monthly operating expenses for Year 3, Year 2, and Year 1.